![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: To report the observations on various bleeding manifestations in children with immune thrombocytopenic purpura (ITP) having severe thrombocytopenia (platelet count (PC) < 20,000/μl) and to compare the differences in bleeding manifestations at levels of PC at < 10,000/μl compared with between 10,000 and 20,000/μl.
Study design: It is a retrospective analysis of bleeding manifestations in children with ITP (n = 58) having severe thrombocytopenia recorded between July 1999 and June 2002. A total of 164 episodes of severe thrombocytopenia were observed. During 31 episodes (18.9%), no bleeding manifestations were observed. When bleeding was observed cutaneous bleeds were the commonest manifestations occurring in 124 episodes. Of these 124 instances, in 82 (66.1%) episodes only cutaneous bleeding was observed while in remaining 42 (33.9%) episodes cutaneous bleeding was associated with other bleeding sites. Other common bleeds observed included epistaxis 22 (13.4%), oral bleeding 21 (12.8%) and gastro-intestinal bleeding 5 (3.04%).
Comparison of the bleeding manifestations during episodes when the PC was < 10,000/μl and those between 10,000 and 20,000/μl showed that in 76.6% episodes with the count at > 10,000/μl no or only cutaneous bleeds were observed (clinically mild disease) compared to 59.45% episodes with episodes having PC < 10,000/μl (z score 2.37, p < 0.05). There was no statistically significant difference in proportion of patients having clinically mild disease during acute or chronic phase of the disease.
Conclusion: During episodes of severe thrombocytopenia, most children have clinically mild disease. When the PC is < 10,000/μl clinically mild disease is observed less often compared to episodes with PC 10,000–20,000/μl. Based on these observations, it can be recommended that during severe thrombocytopenia, particularly when the PC is between 10,000–20,22,000/μl, patients can be safely managed with watchful waiting without any specific therapeutic intervention.